Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Autolus Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Tue Apr 7, 6:00AM CDT

LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates  GlobeNewswire - Fri Mar 27, 6:00AM CDT

AUCATZYL ® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL ® UK launch underway following successful...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics Faces Widening Losses as Analysts Slash Expectations Ahead of Earnings Barchart - Thu Mar 26, 4:01PM CDT

Barchart Research What to Expect from AUTL Earnings AUTL Generated March 26, 2026 Current Price $1.2900 EPS Estimate $-0.31 Consensus Rating Strong Buy Average Move 9.00% Autolus Therapeutics Faces Widening...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 GlobeNewswire - Mon Mar 16, 3:10PM CDT

LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Tue Feb 24, 6:00AM CST

LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Feb 4, 7:57AM CST

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 GlobeNewswire - Mon Jan 12, 6:00AM CST

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipates...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform Business Wire - Tue Jan 6, 8:00AM CST

Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform GlobeNewswire - Tue Jan 6, 8:00AM CST

SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering...

AUTL : 1.4750 (-1.01%)
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 GlobeNewswire - Mon Dec 8, 2025

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cells All patients show deep B-cell...

AUTL : 1.4750 (-1.01%)

Barchart Exclusives

Tesla Is Allegedly Working on a Cheaper EV (Finally). Does That Make TSLA Stock a Buy Here? Barchart - 10 minutes ago
Despite reports of a smaller, cheaper SUV plus expanding energy and AI bets to help the long‑term story, TSLA stock still trades at over 200 times forward earnings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.